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Abstract
Lrf has been previously described as a powerful proto-oncogene. Here we surprisingly
demonstrate that Lrf plays a critical oncosuppressive role in the prostate. Prostate specific
inactivation of Lrf leads to a dramatic acceleration of Pten-loss-driven prostate tumorigenesis
through a bypass of Pten-loss-induced senescence (PICS). We show that LRF physically interacts
with and functionally antagonizes SOX9 transcriptional activity on key target genes such as MIA,
which is involved in tumor cell invasion, and H19, a long non-coding RNA precursor for an Rb-
targeting miRNA. Inactivation of Lrf in vivo leads to Rb down-regulation, PICS bypass and
invasive prostate cancer. Importantly, we found that LRF is genetically lost, as well as down-
regulated at both the mRNA and protein levels in a subset of human advanced prostate cancers.
Thus, we identify LRF as a context-dependent cancer gene that can act as an oncogene in some
contexts but also displays oncosuppressive-like activity in Pten−/− tumors.
Lrf (also known as Pokemon, FBI-1 and OCZF) is a member of the POK (POZ/BTB and
Krüppel) transcription factor family1-4 with important roles in cellular differentiation and
oncogenesis5-9. We have previously shown that LRF is highly expressed in non-Hodgkin's
lymphoma tissues and acts as a bona fide proto-oncogene through its ability to directly
repress the expression of the tumor suppressor ARF1. Recently, overexpression of LRF has
been described in different types of human cancers of various origins, such as non-small cell
lung cancer (NSCL), breast cancer, and ovarian cancer10-14, reinforcing the role of LRF as
an important proto-oncogene in multiple tissues.
Here we showed that Lrf inactivation profoundly promotes the progression of Pten-loss-
driven prostate tumorigenesis by activating SOX9-dependent oncogenic pathways to bypass
Pten-loss-induced cellular senescence (PICS) and promote proliferation, survival and
invasion. Importantly, expression of LRF is lost in a subset of human advanced prostate
cancer. Thus, these results suggest a context dependent role for Lrf in tumorigenesis.
RESULTS
Conditional inactivation of Lrf promotes Pten-loss-driven prostate tumorigenesis
In order to assess the possible proto-oncogenic role for LRF in prostate cancer development,
we generated a transgenic mouse with prostate-specific overexpression of Lrf.
Unexpectedly, we found that over-expression of Lrf in the prostate epithelium was
insufficient to trigger any sign of neoplastic transformation (Supplementary Fig. 1). At the
same time, we also generated mice with conditional inactivation of Lrf in the prostate
(following a strategy described previously15), expecting them to show a profound
suppression in tumor development when crossed with mice harboring genetic deletion of
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tknown prostate tumor suppressors such as Pten. Specifically, we crossed Pb-Cre4 transgenic
mice (expressing Cre after puberty in the prostatic epithelium16) with Lrfflox/flox, Ptenflox/flox,
or Ptenflox/flox;Lrfflox/flox mice to conditionally inactivate Lrf and Pten in the prostate
(Lrfflox/flox;Pb-Cre4, Ptenflox/flox;Pb-Cre4 and Ptenflox/flox;Lrfflox/flox;Pb-Cre4 mutant mice).
Inactivation of Lrf alone in the prostate did not lead to any pathological changes in any
prostate lobes (n=10 mice) of 11 week-old mice (Fig. 1a). Strikingly, however,
histopathological analysis using hematoxylin/eosin (H&E) (Fig. 1a, upper panel),
pancytokeratin (Pan-K) (Fig. 1a, middle panel) and smooth muscle actin (SMA) (Fig. 1a,
lower panel) staining showed a totally unexpected, highly penetrant invasive prostatic
adenocarcinoma as early as 11 weeks in the Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double mutants.
In line with our previous report15, at this age only high-grade PIN was found in the
Ptenflox/flox;Pb-Cre4 (n=10) (Fig. 1a and 1b for the quantification of the invasive prostate
cancer penetrance).
To further analyze the consequences of Lrf inactivation on Pten-null driven prostate cancer,
we followed cohorts of Ptenflox/flox;Pb-Cre4 and Ptenflox/flox;Lrfflox/flox;Pb-Cre4 mice by
monthly magnetic resonance imaging (MRI) analysis. In agreement with previous reports17,
MRI detected the presence of tumors in the prostates of 6-month-old Ptenflox/flox;Pb-Cre4
mice (Fig. 1c). These tumors were significantly enlarged in the age-matched
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 cohort as compared to those of Ptenflox/flox;Pb-Cre4 mice in
terms of both tumor volume (Fig. 1c, d) and weight (Fig. 1e-g).
To test whether the drastic acceleration in prostate tumorigenesis described in the
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 mice would affect long-term survival, we followed a further
cohort of mutant mice over 80 weeks. Kaplan-Meier cumulative survival analysis revealed
that concomitant loss of Lrf and Pten leads to lethal prostate tumors around 13 months (Fig.
1h-j). The Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double mutant mice either died or were
euthanized due to extensive tumor burden (Fig. 1h, i) while most Ptenflox/flox;Pb-Cre4
mutant mice survived beyond 13 months (Fig. 1j). None of the Lrfflox/flox;Pb-Cre4 and WT
control mice died during this period, suggesting that loss of Lrf in combination with Pten
deficiency has a profound effect on the survival of the mutant mice. Thus loss of Lrf
dramatically accelerates the progression of Pten-loss-driven prostate tumors, leading to
massive tumor growth, early stroma invasion and lethal prostate cancer. To further define
whether Lrf has tumor suppressive-like functions in prostate cancer, we followed a cohort of
wild type and Lrfflox/flox;Pb-Cre4 mutant mice over a period of 2 years. 16-18 month-old
Lrfflox/flox;Pb-Cre4 mutants developed PIN in the ventral and dorsolateral lobes (~17%; data
not shown). Even though the low disease penetrance affected the statistical power of this
analysis, overall these results suggest that loss of Lrf can favor both tumor initiation and
progression in prostate cancer.
Inactivation of Lrf overcomes Pten-loss induced cellular senescence and promotes
proliferation, survival and invasion
Next, we attempted to define the cellular and molecular mechanisms underlying the
functions of Lrf that suppress tumor formation in Ptenflox/flox;Pb-Cre4 mice. We had
previously described that Pten-loss-induced senescence (PICS) represents an important fail-
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tsafe mechanism for counteracting tumor progression in prostate15,18. We therefore tested the
cellular senescence response in Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double mutant mice. To this
end, prostate sections of the various genotypes were analyzed by senescence-associated
beta-galactosidase staining (SA-β-gal). As shown in Fig. 2a, a strong cellular senescence
response was observed in the Ptenflox/flox;Pb-Cre4 mice, yet was dramatically reduced in the
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double mutant mice, suggesting that loss of Lrf in a Pten-null
context can yield an unexpected bypass of the senescence response (Fig. 2b for
quantification).
We then investigated the mechanisms that could explain this surprising senescence bypass.
Along with other laboratories, we have previously demonstrated that the PICS program in
the prostate is critically dependent on induction of Trp53, p27, and Smad415,19,20. We
therefore compared the status of p53, p27, and Smad4 proteins in Ptenflox/flox;Pb-Cre4 and
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double mutant prostate tumors. IHC staining and Western
Blot analysis showed that p53, p27, and Smad4 were similarly induced in the
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double mutant as compared to the Ptenflox/flox;Pb-Cre4
single mutant mice (Fig. 2c-d). Furthermore, to ensure that the ability of p53 to regulate its
downstream target genes was not impaired in the Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double
mutant mice, we performed qPCR analysis for p21 and Mdm2 as readout for p53 activity. A
similar induction of both transcripts was observed in the Ptenflox/flox;Lrfflox/flox;Pb-Cre4 and
the Ptenflox/flox;Pb-Cre4; mutant mice (Supplementary Fig. 2a-b), suggesting that p53
function in the Ptenflox/flox;Lrfflox/flox;Pb-Cre4 prostates was intact, and that the evasion of
cellular senescence response in Ptenflox/flox;Lrfflox/flox;Pb-Cre4 mutants was attributable to a
distinct cellular pathway. Additionally, in agreement with the previously reported role for
this gene in ARF transcriptional repression1, we did observe an induction of p19Arf in
Lrf;Pten double null mouse embryonic fibroblasts (MEFs) (Supplementary Fig. 2c) and
murine prostates when compared to their Pten-null counterparts (Fig. 2c lower panel and
2d). These findings are fully coherent with previous studies in which we have proven
genetically that Arf does not play a tumor-suppressive function in the mouse prostate on its
own or, critical to this study, upon concomitant loss of Pten18,21. This notion has been
further corroborated by our own as well as other investigators’ previous analyses on human
specimens, which have shown that complete loss of p14ARF is extremely rare in human
prostate cancer, and that increased ARF abundance unexpectedly correlates with disease
aggressiveness21,22. The senescence bypass observed in Ptenflox/flox;Lrfflox/flox;Pb-Cre4
double mutants was also accompanied by a differential rate in proliferation as compared to
the Ptenflox/flox;Pb-Cre4 mutant. As shown in Fig. 2e, there was a significant increase in the
Ki67 positive cells in the Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double mutants as compared to the
Ptenflox/flox;Pb-Cre4 mutants, providing evidence that loss of Lrf confers a proliferative
advantage in a Pten deficient prostate (Fig. 2f for quantification). In addition, Western Blot
analysis for cleaved caspase 3 revealed that apoptosis in Ptenflox/flox;Lrfflox/flox;Pb-Cre4
double mutants prostate tumors was significantly decreased as compared to the
Ptenflox/flox;Pb-Cre4 mutants (Fig. 2g). Thus, inactivation of Lrf bypasses PICS, favoring
proliferation, survival, and invasion even though p53, p27 and Smad are seemingly
unaffected.
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tLrf deficiency promotes cancer by activation of a Sox9-dependent pathway
We therefore hypothesized that Lrf inactivation could transcriptionally perturb yet another
pro-senescence pathway and performed transcriptome analysis using prostates from 12-week
old mice of WT, Lrfflox/flox;Pb-Cre4, Ptenflox/flox;Pb-Cre4, and Ptenflox/flox;Lrfflox/flox;Pb-
Cre4 genotypes (3 mice per genotype). 567 genes were found to be significantly up-
regulated and 482 genes down-regulated by at least 1.5 fold (p<0.01) in the
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double mutants as compared to the Ptenflox/flox;Pb-Cre4
mutants (Supplementary Table 1). Melanoma inhibitory activity 1 (Mia1) and Deleted in
Malignant Brain Tumors 1 (Dmbt1) were two of the most substantially up-regulated genes in
the ventral as well as in the anterior lobes of the Ptenflox/flox;Lrfflox/flox;Pb-Cre4 prostate
(Supplementary Fig. 3a). Interestingly, both genes are well characterized transcriptional
targets of Sry (sex determining region Y)-box 9 (Sox9)23-25, although no increase in the
levels of Sox9 mRNA was detected in Ptenflox/flox;Pb-Cre4 versus Ptenflox/flox;Lrfflox/flox;Pb-
Cre4 genotypes (Fig. 3a). Furthermore, we performed unbiased Opossum26-28, Ingenuity,
and GSEA29,30 pathway analysis on our transcriptome data to gain mechanistic insights into
the function of LRF in prostate tumorigenesis. Interestingly, Opossum analysis
demonstrated that SOX9 is one of the top 10 transcription factors containing over-
represented transcription factor binding sites in co-expressed genes (Supplementary Table
2), which is consistent with our hypothesis. In addition, by using other two independent
bioinformatics tools such as Ingenuity pathway analysis (IPA) and Gene Set Enrichment
Analysis (GSEA), we found that the most significantly enriched gene-categories in the
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 signature are ‘cellular movement’, ‘cell death and survival’
and ‘cellular growth and proliferation’ (Supplementary Table 3 and Supplementary
Table 4), which is consistent with the aggressive nature of the Ptenflox/flox;Lrfflox/flox;Pb-
Cre4 prostate tumors we observed by histopathological and molecular analyses (Fig. 1a-b,
Fig. 2e, g).
Given that SOX9 has been shown to play important oncogenic functions in the prostate both
in vitro and in vivo31,32, we tested whether Sox9 and Lrf would functionally cross-talk
during prostate cancer development (Fig. 3). We first performed qPCR analysis of Mia1,
and Dmbt1 mRNAs to confirm the findings of the transcriptome analysis. Indeed, Mia1 and
Dmbt1 mRNA were highly up-regulated in Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double mutants
as compared to Ptenflox/flox;Pb-Cre4 mice (Fig. 3a). Since Sox9 expression is known to be
markedly induced in the Pten-deficient prostate31, we performed qPCR, WB and IHC
analyses to determine whether the concomitant loss of Lrf and Pten would affect Sox9
expression. Sox9 protein was expressed in both basal cells and luminal cells of the normal
mouse prostate, but comparably induced in the Ptenflox/flox;Pb-Cre4 mutant mice as well as
the Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double mutants (Fig. 3a-b, k). On this basis, we
hypothesized that the profound and differential increase in the expression of Sox9 target
genes observed in the Pten-Lrf double null prostates was due to an increase in the Sox9
transcriptional activity rather than expression levels.
LRF mainly acts as a transcriptional repressor1 and SOX9 as a transcriptional activator23.
We therefore tested whether LRF would oppose the transcriptional activity function of
SOX9. To this end, we performed transactivation assays with a luciferase construct
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tcontaining multiple SOX9 binding sites33 in PC3 and DU145 human prostate cancer cell
lines which express a low level of endogenous LRF (Fig. 3c). LRF efficiently abrogated the
ability of SOX9 to transactivate the reporter gene in a dose-dependent manner in PC3 and
DU145 (Fig. 3d, Supplementary Fig. 3c). Since the multimeric SOX9 reporter is an
artificial responsive element devoid of LRF binding sites, we next determined whether LRF
was able to repress the SOX9 transcriptional activity through a direct physical interaction.
To this end, we performed an immunoprecipitation assay in PC3, and RWPE-1 cells using
an anti-SOX9 antibody and a control IgG. Anti-SOX9 antibody specifically pulled down
endogenous LRF in PC3 and RWPE-1 cells (Fig. 3e left and middle panel), suggesting a
physiological interaction between SOX9 and LRF in human prostate cells. Furthermore, an
immunoprecipitation assay using Ptenflox/flox;Pb-Cre4 mouse prostates that express high
levels of both Lrf and Sox9 also revealed a direct interaction between Lrf and Sox9 in vivo
(Fig. 3e right panel).
To demonstrate whether SOX9 target genes, such as MIA1 and DMBT1, were also co-
regulated by LRF in human prostate cells, we inactivated LRF by a short hairpin RNA
(shRNA) in RWPE-1 cells, which express a high level of endogenous LRF (Fig. 3c).
Subsequent qPCR analysis revealed that MIA1 and DMBT1 mRNAs were up-regulated
when LRF was inactivated as compared to the control shRNA (Fig. 3f). Importantly, ChIP
assays with anti-LRF and anti-SOX9 antibodies confirmed that both proteins specifically
bind the promoters of MIA1 and DMBT1 (Fig. 3g). These data demonstrate that MIA1 and
DMBT1 are SOX9 target genes in human prostate cells as well, and that their expression
critically depends on the relative amount of LRF and SOX9.
Thus, the exacerbation of SOX9 oncogenic activities in prostate cancer as a consequence of
LRF loss could drive hyper-proliferation as well as enhance invasiveness through target
genes such as MIA1 and DMBT134-44. On this basis, we speculated that Sox9 hyper-activity
in the Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double mutant mice might also be responsible for the
senescence bypass. In this respect, we noticed that the Sox9 target gene H19, which encodes
a precursor non-coding RNA for miR67545, was strongly up-regulated in the
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double mutant mice as compared to Ptenflox/flox;Pb-Cre4
mutant mice (Fig. 3h left panel, Supplementary Fig. 3a). Given that miR675 is known to
target the tumor suppressor Retinoblastoma (Rb)46, a key regulator of the cellular
senescence response47, we tested whether miR675 expression was concomitantly increased
in Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double mutant mice. Indeed, expression levels of miR675
are far higher in the prostates of Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double mutant mice than in
those of Ptenflox/flox;Pb-Cre4 mice (Fig. 3h right panel, Supplementary Fig. 4 ).
Accordingly, H19 mRNA was also strongly induced when LRF was transiently inactivated
in RWPE1 cells (Fig. 3i). Furthermore, both SOX9 and LRF were found to bind to the H19
promoter as shown by ChIP assay (Fig. 3j) suggesting that H19 is a direct target for LRF
and SOX9 in prostate cell. Western blot and IHC analysis confirmed that Rb protein
expression was clearly down-regulated in Ptenflox/flox;Lrfflox/flox;Pb-Cre4 double mutant
mice prostate (Fig. 3k, l). As expected, Rb reduction in mouse Pten-Lrf double-null
prostates determined the up-regulation of a panel of E2F1 proven transcriptional target
genes (Supplementary Table 5), although, interestingly, it has been shown recently that the
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tregulation of senescence by Rb in the mouse prostate is at least partly independent of E2F
function48. However, although the Rb/E2F pathway was clearly affected in
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 prostate cancer, we cannot rule out the possibility that loss of
Lrf may also affect PICS by perturbing additional unknown pro-senescence pathways.
Taken together these results demonstrate that during prostate tumorigenesis, the
oncosuppressive function of Lrf directly impinge on the oncogenic activity of Sox9, and that
Lrf loss in the prostate favors: i) senescence bypass, ii) increase of proliferation rate, iii)
apoptosis resistance, and iv) invasive potential.
Loss of Lrf expression in human prostate cancer
We next investigated the status of LRF in human prostate cancer by first analyzing the
expression of LRF mRNA and protein, respectively, in Oncomine database plus a
customized human prostate cancer Tissue Micro-Array (TMA) (see also reference49). In line
with our mouse data, our analysis of prostate cancer expression profile datasets50-54,
revealed that LRF is under-expressed in prostate cancer, and down-regulated upon tumor
progression to high Gleason score and metastasis (Fig. 4a-d, Supplementary Fig. 5, and
reference49). Additionally, we analyzed human prostate cancer expression array data from
patients stratified by prostate cancer recurrence55 (Fig. 4d), and found that LRF transcript
levels are significantly decreased in patient samples demonstrating a greater propensity for
tumor recurrence (Fig. 4d). As the LRF transcript is extremely C/G rich (70%), which may
affect the specificity in the annealing of the probe, we analyzed multiple prostate cancer
expression profile data sets (11 in total)50-60; of these, 6 clearly showed down-regulation of
LRF in human prostate cancer/metastasis, while 3 did not permit any clear conclusion, and 2
showed no significant changes in the expression of LRF between normal versus prostate
cancer samples (see Supplementary Table 6 for details on all the interrogated data sets and
criteria followed for the analysis).
To further define the cause of LRF loss in human cancer, we employed a multifaceted
approach. Strikingly, a comparative genomic hybridization (CGH) analysis for genetic
alterations involving the region of LRF on chromosome 19 showed that 18% (10 out of 55
patients) of advanced prostate cancer harbored monoallelic loss of LRF (Supplementary
Fig. 6a: see also reference49). Additionally, we recently discovered that LRF levels are
strongly down-regulated by the miR-17 family (including miR-20a, -93 and -106b61, and
Supplementary Fig. 6b-e), which regulates LRF mRNA translation more than transcript
degradation61, and which also targets PTEN62. Intriguingly, the miR106b~25 cluster is
located in intron 13 of the of minichromosome maintenance complex component 7 (MCM7)
gene, one of the most genetically amplified loci in human advanced prostate cancer63.
Accordingly, we found this miRNA family markedly up-regulated in human prostate cancer
(Fig. 4e)53, while IHC staining with anti-LRF on a TMA which included 50 human samples
of primary prostate cancer (see Supplementary Table 7 for detail information) confirmed
loss of LRF protein in approximately 50% (22/42) of biopsied specimens analyzed (Fig. 4f,
8 out of 50 prostate cancer samples were excluded from the analysis for technical reasons).
Importantly, we also observed a significant association between LRF and PTEN protein loss
in these 42 prostate cancer specimens (Chi-square, p=0.0123) (Fig. 4g), further suggesting a
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tcooperative oncosuppressive role for LRF and PTEN in human prostate cancer (see also
reference49). Lastly, we performed immunohistochemistry for LRF and SOX9 on the same
TMA and found that 20 cases out of 36 human advanced prostate tumors (Gleason scores
8-10) (see Supplementary Table 7 for detail information) were characterized by high levels
of SOX9 expression (Supplementary Fig. 7a-b). Importantly, 12 out of these 20 also
showed a concomitant loss of LRF protein (Supplementary Fig. 7a-b).
DISCUSSION
In this work, we have unexpectedly demonstrated that loss of Lrf accelerates the progression
of Pten-loss driven tumors in the prostate. This notion is further corroborated by the lack of
tumorigenesis and any discernible phenotype in mice that overexpressed LRF specifically in
the prostate epithelium (Probasin (Pb)-Lrf transgenic lines, data not shown). LRF can
therefore critically contribute to tumorigenesis not only when overexpressed but also when
down-regulated, depending on its cellular and genetic milieu. In mechanistic terms, we
demonstrate that Lrf loss dramatically accelerates the progression of Pten-loss-driven
prostate tumors by super-activating the oncogenic transcriptional activity of Sox9, a key step
that in prostate cancer leads to bypass of PICS and the activation of pro-proliferative/
survival and invasive transcriptional Sox9-dependent signatures (Fig. 4h).
Importantly, we also defined that LRF is genetically lost as well as transcriptionally and
post-transcriptionally down-regulated in human prostate cancers, and that loss of LRF
protein strongly correlates with loss of PTEN protein in advanced prostate cancer. Notably,
we discovered that LRF and PTEN transcripts are both targets of the miR-106b~25 cluster
located in the intron 13 of MCM762. MCM7 is one of the most amplified oncogenes in
human prostate cancer, and is highly correlated with tumor progression, biochemical
recurrence, and distant metastases63. In addition, it has been shown that Rb negatively
regulates DNA replication through a direct interaction with MCM764. Thus, downregulation
of Rb due to LRF/PTEN concomitant inactivation may also promote the oncogenic activities
of MCM7. This ability to simultaneously down-regulate PTEN and LRF therefore defines a
new important causal link between MCM7/miR-106b~25 amplification and prostate
tumorigenesis. Others important genetic events such as TMPRSS2-ERG fusion or p53
mutation/loss have been identified as frequent events in human prostate cancer65-69, and are
strongly associated with loss of PTEN. Robust evidence of functional cooperation between
these genetic lesions has been demonstrated by a plethora of different studies, particularly
those utilizing specific mouse models15,70,71. Given that loss or down-regulation of LRF is
also associated with PTEN loss in advanced prostate tumors, it is conceivable that LRF
might have important oncosuppressive functions in the context of TMPRSS2-ERG fusion or
p53 loss/mutation pathways, in counteracting the progression of prostate tumors as well as
the response to specific treatments 49.
Thus genetic analysis in mouse models has identified an unpredicted dual role of LRF in
oncogenesis through its ability to control major tumor pathways such as ARF/p53, Rb and
SOX9, in a context- and tissue-dependent manner, and has defined a novel oncogenic
pathway triggered by LRF loss, and pathogenetically linked to the amplification of the
MCM7 locus in advanced human prostate cancer.
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METHODS
Generation of Pten and Lrf mutant mice
Ptenflox/flox, Lrfflox/flox, and Pb-Cre4 were maintained as described1,15. To generate the
prostate-specific deletion of Pten and Lrf, female Ptenflox/flox;Lrfflox/flox mice were crossed
with male Pb-Cre4 transgenic mice16. For genotyping, tail DNA was subjected to
polymerase chain reaction analysis with the following primers (see Supplementary Table 8
for detail information). For Ptenflox/flox, primer PtenLoxP_Fwd and PtenLoxP_Rev were
used. For Lrfflox/flox, the following primers were used: PCFW1, PCFW2, PCFW3, PCRV,
PCNeo. All experimental animals were kept in a mixed genetic background of C57BL/6J
X129/Sv. Animal experiments were performed in accordance with the guidelines of the
Institutional Animal Care and Use Committee.
Plasmids and cell lines
The pcDNA3.1-XP-LRF plasmid, which expresses an Xpress-tagged LRF, was generated by
cloning the full-length human cDNA into the pcDNA3.1/HisC plasmid. The pcDNA3-Flag-
SOX9 plasmid72 was a gift from Dr. P. Berta (Human Molecular Genetics Group, Institut de
Genetique Humane, Montpellier, France) and the SOX9-regulated luciferase reporter (4x48-
p89-luciferase)33was provided by Dr. B. de Crombrugghe (Department of Molecular
Genetics, University of Texas MD Anderson Cancer Center, Houston, TX).
PC3, Du145, LNCaP, RWPE-1, and PWR-1E cells were obtained from American Type
Culture Collection (Manassas, VA). PC3, Du145, and LNCaP cells were maintained in
DMEM with 10% FBS. RWPE-1 and PWR-1E cells were cultured in Keratinocyte Serum
Free Medium (K-SFM) supplemented with bovine pituitary extract (BPE) and human
recombinant epidermal growth factor (EGF).
shRNA constructs and lentiviral production
shRNA constructs were obtained from Open Biosystems in lentiviral cassettes. An shRNA
with high LRF knockdown efficiency was used, with an shRNA for GFP used as a control.
As described previously73, lentivirus was made using a three-plasmid packaging system.
Briefly, shRNAs in the pLKO.1-puro vector were co-transfected into 293T cells along with
expression vectors containing the gag/pol, rev and vsvg genes. Lentivirus was harvested 48 h
after transfection, and 5 μg/ml polybrene was added. Subconfluent RWPE-1 cells were
infected with harvested lentivirus, and were selected in 2 μg/ml puromycin for 1 week.
Senescence and apoptosis assays
SA-β-Gal activity in prostate tissue was revealed with the senescence detection kit
(Calbiochem) on 6μm thick frozen sections. For apoptosis analysis, dewaxed and rehydrated
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apoptotic cells were identified by positive TUNEL staining.
Western blot, immunoprecipitation and immunohistochemistry
For western blot, cell lysates were prepared with RIPA buffer (1 × PBS, 1% Nonidet P40,
0.5% sodium deoxycholate, 0.1% SDS and protease inhibitor cocktail (Roche)). The
following antibodies were used for western blotting: rat monoclonal anti-p19Arf (5-C3-1;
Calbiochem), rabbit polyclonal anti-p53 (CM5; Novocastra), rabbit polyclonal anti-p21
(C-19; Santa Cruz), mouse monoclonal anti-p27 antibody (BD Bioscience), rabbit
polyclonal anti-p16 (M-156; Santa Cruz), rabbit polyclonal anti-sox9 antibody (Millipore),
mouse polyclonal antibody to β-actin (Sigma-aldrich), mouse monoclonal anti-HSP90 (BD
Biosciences), total caspase 3, cleaved caspase 3 and GAPDH (Cell Signaling Technology).
For immunoprecipitation, PC3 cell lysates were prepared in EBC buffer (50 mM Tris pH
7.5, 120 mM NaCl, 0.5% NP-40) and subjected to immunoprecipitation with 2 μg anti-Sox9
antibody above. The immunoprecipitates were washed with NETN buffer (20 mM Tris, pH
8.0, 100 mM NaCl, 1 mM EDTA and 0.5% NP-40) and analyzed by SDS-PAGE. For
immunohistochemistry (IHC), tissues were fixed in 10% formalin and embedded in paraffin
in accordance with standard procedures. Sections were stained for phospho-Akt (Ser 473)
antibody (Cell Signalling), PTEN (Ab-2; NeoMarkers), Ki-67 (Novocastra), p19Arf (5-C3-1;
Calbiochem), p21 (F-5; Santa Cruz), p53 (FL-393; Santa Cruz), androgen receptor (N-20;
Santa Cruz), smooth muscle actin (Abcam), pancytokeratin (Sigma-aldrich), and p63
(550025; Becton Dickson Transduction Lab).
Transfection and Luciferase reporter assay
One day before transfection, cells were plated into 24-well plates at a density of 70-80%.
The cells were transfected with the plasmids DNA and lipofectamine 2000 (Invitrogen) for
24 hours according to the manufacturer's recommendation. 48 hours post-transfection, cells
were lysed with passive lysis buffer and analyzed for luciferase activity using the Dual-
luciferase assay system (Promega). pRL-SV40-Renillar was used a control for transfection
efficiency.
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation (ChIP) assay was performed as described previously74.
Briefly, formaldehyde was added at 1% to PC3 cells or RWPE-1 cells for 5 minutes to
cross-link proteins and DNA. Cells were then washed and re-suspended in lysis buffer (1%
sodium dodecyl, 10 mM EDTA, and 50 mM Tris-HCI at pH 8.1) with 1 mM
phenylmethylsulfonyl fluoride, 1 μg/mL aprotinin, and 1 μg/mL pepstatin-A added. After
brief sonication, cell lysates were cleared by centrifugation and were diluted 10-fold with
dilution buffer (0.01% sodium dodecyl, 1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-
HCl at pH 8.1, and 167 mM NaCl) containing protease inhibitors. Anti–Sox9 (C-20, Santa
Cruz) and anti–LRF (Bethyl Laboratory) or control IgG were added at 4°C overnight with
rotation. Immunoprecipitated complexes were collected using Protein G Dynabeads
(Invitrogen) and then washed with Low Salt Immune Complex Wash Buffer, High Salt
Immune Complex Wash Buffer, LiCl Immune Complex Wash Buffer, and TE buffer. 5 M
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tNaCl was added in order to the resulting precipitants to reverse the formaldehyde cross-
linking by heating at 65°C for 6 hours. Following phenol/cloroform extraction and
precipitation with ethanol, pellets were re-suspended in TE buffer and subjected to
quantitative PCR analysis using forward and reverse primers selected from the H19, MIA1,
DMBT1, and CXCL5 promoter sequences (see Supplementary Table 8 for detail
information). Quantitative PCR was used to amplify immunoprecipitated DNA using
QuantiTect SYBR Green PCR kit (QIAGEN). Relative enrichment of the pulled down
chromatin for LRF and SOX9 was normalized IgG control using the comparative CT
method75.
RNA isolation, gene expression profiling and quantitative PCR analysis
Total RNAs were purified from AP, VP, or indicated cell lines using the RNAeasy Mini Kit
(Qiagen) and treated with RNase-free DNase set (Qiagen). For gene expression profiling
experiments, RNAs from AP or VP were labeled and hybridized Affymetrix GeneChip® HT
Mouse Genome 430 PM arrays by the Beth Israel Deaconess Medical Center Genomics and
Proteomics Center. For quantitative PCR analysis, 2 μg total RNAs were reverse transcribed
into cDNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche Applied
Science). Taqman quantitative PCR analysis (Applied Biosystems) was performed in the
Biopolymers Facility at Harvard Medical School using an Applied Biosystems 7900 HT
Fast instrument according to the manufacturer's protocol. Each target was run in triplicate
and expression level was normalized to mouse glucuronidase beta (GusB) or human β-actin.
For miRNA profiling, total RNA was isolated from AP and subjected to global miRNA
profiling with Nanostring technology. A total of 578 miRNAs were evaluated using the
nCounter® Mouse miRNA Expression Assay Kit.
Tissue microarray analysis
The tissue microarray (TMAs) used in this studied was constructed at the Memorial Sloan-
Kettering Cancer Center (MSKCC) or purchased from US Biomax, Inc., and stained in
Pathology and Molecular Cytology Core Facilities as described previously1.
Statistical analysis
Data were analyzed using unpaired t-test (GraphPad Prism, GraphPad Software, Inc.).
Values of P < 0.05 were considered statistically significant. *P < 0.05; **P < 0.01; ***P <
0.001. The mean ± s.d. of three or more independent experiments is reported.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tEditorial Summary (PF)
The transcription factor Lrf/Pokemon was previously described as an oncogene in non-
Hodgkin's lymphoma. Now, Pier Paolo Pandolfi and colleagues report that loss of Lrf
accelerates the progression of invasive prostate tumorigenesis in Pten−/− mice and shows
evidence of monoallelic loss in 18% (10 out of 55 patients) of advanced prostate cancer.
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tFigure 1. Conditional deletion of Lrf in mouse prostate dramatically promotes Pten-loss-induced
prostate tumorigenesis
(a) H&E, anti-Pan-cytokeratin (Pan-K) and anti-smooth muscle actin (SMA) staining of WT,
Lrfflox/flox;Pb-Cre4, Ptenflox/flox;Pb-Cre4, and Ptenflox/flox;Lrfflox/flox;Pb-Cre4 prostates. (b)
Percentage of invasive prostate carcinoma in Ptenflox/flox;Pb-Cre4, and
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 mice. (c) MRI analysis of Ptenflox/flox;Pb-Cre4 and
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 prostates. (d) Tumor volume quantification. (e) Anterior
prostate (AP) tumor weight from 3 month-old Ptenflox/flox;Pb-Cre4, and
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tPtenflox/flox;Lrfflox/flox;Pb-Cre4 mice (n=5). (f) Ventral prostate (VP) tumor weight from 6, 7,
9 month-old Ptenflox/flox;Pb-Cre4 (n=5, grey bars), and Ptenflox/flox;Lrfflox/flox;Pb-Cre4 mice
(n=5, black bars). (g) Dorsolateral prostate (DLP) tumor weight from 6, 7, 9 month-old
Ptenflox/flox;Pb-Cre4 (n=5, grey bars), and Ptenflox/flox;Lrfflox/flox;Pb-Cre4 mice (n=5, black
bars). Data are presented as mean ± standard deviation. (h) Representative prostates from
WT, Lrfflox/flox;Pb-Cre4, Ptenflox/flox;Pb-Cre4 , and Ptenflox/flox;Lrfflox/flox;Pb-Cre4 mice 1
year old. (i) Representative H&E staining from Ptenflox/flox;Pb-Cre4 , and
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 mice 1 year old. (j) Cumulative survival of WT (n=20),
Lrfflox/flox;Pb-Cre4 (n=20), Ptenflox/flox;Pb-Cre4 (n=20), and Ptenflox/flox;Lrfflox/flox;Pb-Cre4
(n=11) mice.
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tFigure 2. Loss of Lrf leads to senescence bypass and increased proliferation
(a) Senescence-associated β-galactosidase staining (SA-β-gal) of WT, Lrfflox/flox;Pb-Cre4,
Ptenflox/flox;Pb-Cre4 , and Ptenflox/flox;Lrfflox/flox;Pb-Cre4 prostates of 12 week-old mice
show a significant reduction of senescence in Ptenflox/flox;Lrfflox/flox;Pb-Cre4 prostates as
compared to Ptenflox/flox;Pb-Cre4 prostates. (b) Percentage of SA-b-gal positive cells in the
prostate of 12 week-old Ptenflox/flox;Pb-Cre4, and Ptenflox/flox;Lrfflox/flox;Pb-Cre4 mice
(number of mice=3/genotype, number of cells=1000/field, number of fields=10/lobe). (c)
anti-p53, anti-p27 and p19Arf staining in 12 week-old WT, Lrfflox/flox;Pb-Cre4,
Wang et al. Page 19
Nat Genet. Author manuscript; available in PMC 2014 May 28.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tPtenflox/flox;Pb-Cre4 , and Ptenflox/flox;Lrfflox/flox;Pb-Cre4 prostates. (d) Western blot
analysis for Pten, pAkt (Serine 473), Lrf, Smad4, pSmad2, AR, p53, p21, p27, and p19Arf.
(e) Ki-67 staining of WT, Lrfflox/flox;Pb-Cre4, Ptenflox/flox;Pb-Cre4 , and
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 prostates suggests that loss of Lrf and Pten leads to increased
proliferation. (f) Percentage of Ki67 positive cells in the three lobes of WT (light grey bars),
Lrfflox/flox;Pb-Cre4 (grey bars), Ptenflox/flox;Pb-Cre4 (dark grey bars), and
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 (black bars) 12-week-old mice (number of mice=3/genotype,
total cells/lobe=5000). (g) Western blot analysis for cleaved caspase 3, total caspase 3, and
Gapdh of Ptenflox/flox;Pb-Cre4 , and Ptenflox/flox;Lrfflox/flox;Pb-Cre4 12-week-old mice
prostates.
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tFigure 3. Hyper-activation of Sox9 in Pten;Lrf double-null prostate tumors down-regulates Rb
expression through H19/miR675
(a) qRT-PCR analysis of Mia1, Dmbt1, and Sox9 expression in WT (black bars),
Lrfflox/flox;Pb-Cre4 (orange bars), Ptenflox/flox;Pb-Cre4 (red bars), and
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 (blue bars) n=3/genotype 12 week-old mice prostates. (b)
Anti-Sox9 staining of WT, Lrfflox/flox;Pb-Cre4, Ptenflox/flox;Pb-Cre4 , and
Ptenflox/flox;Lrfflox/flox;Pb-Cre4 prostates. (c) Western blot analysis of prostate cells lines for
LRF expression. (d) Dual-luciferase assay with a Sox9-reporter in PC3 cells. (e) Co-
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timmunoprecipitation of SOX9 and LRF from PC3 cells, RWPE-1 cells, and mouse prostate.
(f) shRNA targeting LRF (grey bars) in RWPE-1 cells leads to an increase in MIA1 and
DMBT1 mRNAs expression. Scramble shRNA was used as control (pink bars). (g)
Chromatin immunoprecipitation (ChIP) of MIA1 and DMBT1 promoters using anti-LRF
(yellow bar), anti-SOX9 (green bar) or rabbit IgG (white bars) antibodies. (h) H19 and
miR675 expression in WT (black bar), Lrfflox/flox;Pb-Cre4 (orange bar), Ptenflox/flox;Pb-Cre4
(red bars), Ptenflox/flox;Lrfflox/flox;Pb-Cre4 (blue bars). N=3 mice/genotype were used. (i)
shRNA targeting LRF (grey bar) in RWPE-1 cells leads to an increase in H19 mRNA
expression. Scramble shRNA was used as control (pink bar). Data are presented as mean of
3 independent experiments ± standard deviation. (j) Both LRF (yellow bar) and SOX9
(green bar) bind to H19 promoter as shown by ChIP analysis in RWPE-1 cells. Rabbit IgG
were used as control (white bar). All data are presented as mean of 3 independent
experiments ± standard deviation. (k-l) Rb protein expression in Ptenflox/flox;Lrfflox/flox;Pb-
Cre4 and Ptenflox/flox;Pb-Cre4 prostates as shown by Western blot analysis (k) and
immunohistochemical analysis (l).
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tFigure 4. LRF down-regulation in human prostate cancers correlates with tumor progression
and metastasis
(a-d) LRF mRNA is significantly down-regulated in a subset of primary prostate cancers
and metastasis (Oncomine). (e) Expression analysis of miR20, miR106b, and miR93 in
normal prostate epithelium (grey bars) versus prostate cancer tissue (red bars). (f) IHC
analysis of PTEN and LRF protein expression in high Gleason human prostate cancers
demonstrating that loss of LRF is strongly associated with loss of PTEN. (g) Distribution of
Pten+/LRF+, PTEN+/LRF−, PTEN−/LRF+, and PTEN−/LRF− samples in the cohort of
patients analyzed. (h) Model for the role of LRF in prostate cancer progression.
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